PL320610A1 - Fragments of monoclonal antibodies of immunosuppressive activity - Google Patents

Fragments of monoclonal antibodies of immunosuppressive activity

Info

Publication number
PL320610A1
PL320610A1 PL95320610A PL32061095A PL320610A1 PL 320610 A1 PL320610 A1 PL 320610A1 PL 95320610 A PL95320610 A PL 95320610A PL 32061095 A PL32061095 A PL 32061095A PL 320610 A1 PL320610 A1 PL 320610A1
Authority
PL
Poland
Prior art keywords
fragments
monoclonal antibodies
immunosuppressive activity
immunosuppressive
activity
Prior art date
Application number
PL95320610A
Other languages
English (en)
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL320610A1 publication Critical patent/PL320610A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL95320610A 1994-12-07 1995-11-25 Fragments of monoclonal antibodies of immunosuppressive activity PL320610A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (fr) 1994-12-07 1995-11-25 Fragments d'anticorps monoclonaux possedant une activite immunodepressive

Publications (1)

Publication Number Publication Date
PL320610A1 true PL320610A1 (en) 1997-10-13

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95320610A PL320610A1 (en) 1994-12-07 1995-11-25 Fragments of monoclonal antibodies of immunosuppressive activity

Country Status (19)

Country Link
EP (1) EP0787151A1 (fr)
JP (1) JP2001506122A (fr)
CN (1) CN1168679A (fr)
AR (1) AR002005A1 (fr)
AU (1) AU4256096A (fr)
BR (1) BR9509902A (fr)
CA (1) CA2206471A1 (fr)
CO (1) CO4480041A1 (fr)
CZ (1) CZ172497A3 (fr)
FI (1) FI972430L (fr)
HU (1) HUT77342A (fr)
IL (1) IL116228A0 (fr)
MA (1) MA23739A1 (fr)
NO (1) NO972522L (fr)
PE (1) PE52996A1 (fr)
PL (1) PL320610A1 (fr)
TR (1) TR199501542A2 (fr)
WO (1) WO1996017874A1 (fr)
ZA (1) ZA9510195B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (fr) 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1156060B1 (fr) * 2000-05-12 2007-06-27 GPC Biotech AG Peptides/protéines humaines causant ou menant à la mort de cellules y compris de cellules lymphoides tumorales
EP1156062A1 (fr) * 2000-05-12 2001-11-21 GPC Biotech AG Peptides/protéines immunomodulants et liants à un antigène du CMH classe II humain
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
CA2794499A1 (fr) * 2010-04-01 2011-10-06 Immumomedics, Inc. Utilisation d'anticorps pour reduire le nombre de cellules contenant des antigenes et de cellules dendritiques
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (fr) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Méthode immunothérapeutique allèle spécifique et forme de dosage
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.

Also Published As

Publication number Publication date
BR9509902A (pt) 1997-10-21
AR002005A1 (es) 1998-01-07
AU4256096A (en) 1996-06-26
JP2001506122A (ja) 2001-05-15
CA2206471A1 (fr) 1996-06-13
TR199501542A2 (tr) 1996-07-21
EP0787151A1 (fr) 1997-08-06
CN1168679A (zh) 1997-12-24
NO972522L (no) 1997-08-06
IL116228A0 (en) 1996-03-31
FI972430A7 (fi) 1997-06-06
FI972430A0 (fi) 1997-06-06
NO972522D0 (no) 1997-06-03
ZA9510195B (en) 1996-06-07
WO1996017874A1 (fr) 1996-06-13
CZ172497A3 (en) 1997-10-15
MX9704225A (es) 1997-09-30
HUT77342A (hu) 1998-03-30
FI972430L (fi) 1997-06-06
PE52996A1 (es) 1996-12-12
MA23739A1 (fr) 1996-07-01
CO4480041A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
IL128406A0 (en) Monoclonal antibodies
EP0870826A4 (fr) Nouvelle proteine et anticorps monoclonal specifique a cette derniere
IL136335A0 (en) Monoclonal human natural antibodies
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
IL130143A0 (en) Humanized anti-CD11a antibodies
EP0759071A4 (fr) Anticorps monoclonaux du wt1 et leur emploi
GB9422383D0 (en) Antibodies
PL320610A1 (en) Fragments of monoclonal antibodies of immunosuppressive activity
EP0909278A4 (fr) Immunoglobuline g liee a la nephropathie et anticorps contre celle-ci
IL109232A0 (en) Human monoclonal antibodies and processes and materials for making such antibodies
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
HK1001864A (en) Monoclonal antibody fragments having immunosuppressant activity
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
GB9506425D0 (en) New uses of monoclonal antibodies
GB9615027D0 (en) Monoclonal antibodies
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
PL329866A1 (en) Monoclonal antibody against human mp52
EP0693121A4 (fr) Anticorps monoclonal 88bv59, subclones et procede de production
SG64332A1 (en) Monoclonal antibody
GB9212074D0 (en) Monoclonal antibody
GB9519460D0 (en) Polyclonal antibodies and their use
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210944D0 (en) Monoclonal antibodies and their use